Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Behind Cephalon's Numbers: a Big Cancer Bet and Signs of Skepticism
- The FDA delivered to Cephalon a letter yesterday saying it would not approve expanded indications for its pain drug Fentora until the company gave it more information on how it would prevent the drug from being abused. Even though the Fentora situation is fixable, it's just the sort of headache...
- Blog posts 2008-09-16
Additional Resources
- Salmedix, Inc. Announces Presentation of Clinical Data for Treanda at ASCO
- SAN DIEGO -- Salmedix, Inc. announced today that interim data from two ongoing Phase II trials of TreandaTM (bendamustine HCl; SDX-105) will be presented during a poster discussion session at the 2005 American Society of Clinical Oncology ASCO Annual Meeting to be held in Orlando, Florida, May 13 through 17....
- Research articles 2005-05-11
- Cephalon Q3 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you. Operator Instructions We will take our first question from Jim Birchenough with Lehman Brothers. Jim Birchenough - Lehman Brothers Hi, guys, and congratulations on the quarter, just a question on the settlement agreement. Given your requirements to maintaining a certain cash balance and the settlement...
- Earnings calls 2007-11-08
- Cephalon, Inc. Q2 2008 Earnings Call
- Question-and-Answer SessionThe question and answer session will be conducted electronically. [Operator Instructions]. We will pause just a moment. We'll take our first question from Jim Birchenough with Lehman Brothers. Jim Birchenough - Lehman Brothers Hi, guys. Congratulations on the quarter. I want to start-off with a big picture question...
- Earnings calls 2008-07-29
- Generics Threaten Drugmaker Cephalon's Success
- Biotechnology watchers are measuring success at Cephalon on how quickly the drugmaker can convert patients on its soon-to-go generic blockbuster Provigil to regular users of its narcoleptic successor Nuvigil. As Jim Edwards at BNET Pharma astutely pointed out exactly one year ago, however, competition also threatens to derail...
- Blog posts 2009-09-21
- Cephalon, Inc. Q4 2007 Earnings Call Transcript
- Question-and-Answer Session[Operator Instructions]. Our first question will come Greg Gilbert with Merrill Lynch. Greg Gilbert - Merrill Lynch Thanks. I have a couple. First for Kevin. Can you help us with what level of TREANDA expense you filed in for '08, if possible broken down between launch related versus...
- Earnings calls 2008-02-12
- Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
- First New Agent for CLL Patients Approved by the FDA Since 2001
- Research articles 2008-03-20
- Cephalon Inc. Q3 2008 Earnings Conference Call Transcript
- Question-and-Answer SessionThank you. [Operator Instructions]. We will take our first question from David Buck with Buckingham Research. David Buck - Buckingham Research Group Yes, thanks for taking the question. Just a couple. First on 2009, Frank, you mentioned the potential for promotional claims for individual. Is there potential... the...
- Earnings calls 2008-10-28
- NCCN Updates Non-Hodgkin's Lymphoma Guidelines
- FORT WASHINGTON, Pa. -- The National Comprehensive Cancer Network NCCN announces several new updates to the NCCN Clinical Practice Guidelines in Oncology[TM] Non-Hodgkin's Lymphoma NHL. These changes highlight leading developments in the treatment of NHL and represent the recognized standard for clinical care in oncology in both the community and...
- Research articles 2008-04-22
- Cephalon Inc. Q1 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator We will take our first question from Jim Birchenough with Barclays. Jim Birchenough - Barclays Just wondering on the PROVIGIL number for the quarter, it was down 10%. I'm having trouble reconciling that with the price increase and what seemed to be relatively flat volume trends. Could...
- Earnings calls 2009-05-05
- Cephalon, Inc. Q2 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions We'll go first to Eric Schmidt with Cowen and Company. Eric Schmidt - Cowen and Company Frank, on TREANDA, I think you mentioned that NHL now is the primary driver of growth taking over from CLL a quarter ago. Yet on a quarter-over-quarter basis there...
- Earnings calls 2009-08-04
- << Previous
- page 1 of 1
- Next >>
